TY - JOUR
T1 - Impaired endothelial function in patients with nephrotic range proteinuria
AU - Stroes, Erik S.G.
AU - Joles, Jaap A.
AU - Chang, Peter C.
AU - Koomans, Hein A.
AU - Rabelink, Ton J.
N1 - Funding Information:
This work was supported by the Dutch Kidney Foundation (grant number C 93.1300). A.J.Rabelink is sponsored by a fellowship of the
PY - 1995/8
Y1 - 1995/8
N2 - Proteinuria is associated with increased cardiovascular morbidity and mortality. Release of nitric oxide by the endothelium has been advanced as an important defense mechanism against vessel-wall damage. In the present study we therefore tested the hypothesis that proteinuria is associated with a defect in nitric oxide-dependent vasodilation, by using venous occlusion plethysmography of the forearm in nine patients with nephrotic range proteinuria (>3.5 g/24 hr) and normal renal function (creatinine 83.1 ± 8.7 μmol/liter), eight patients with active glomerulonephritis but normal renal function (creatinine 81.2 ± 5.4 μmol/liter) and low range proteinuria (<1.0 g/24 hr), and ten healthy volunteers. We infused L-NMMA (2 mg/min) to inhibit basal nitric oxide production, serotonin, 0.1, 0.3 and 1.0 ng/kg/min) as an endothelium-dependent vasodilator, and nitroprusside (1, 10, 30 and 100 ng/kg/min) as an endothelium-independent vasodilator into the brachial artery. Administration of L-NMMA decreased basal forearm vascular resistance (FVR) By 30 ± 4% in the nephrotic subjects, 38 ± 4% in the non-nephrotic patients and by 37 ± 2% in the healthy controls (P = 0.15). Upon the highest dose of serotonin FVR decreased in nephrotic subjects by 40 ± 5%, which was less than in non-nephrotic patients (56 ± 3%; P < 0.05) or in healthy controls (55 ± 3%; P < 0.05). The maximal decrease in FVR upon nitroprusside infusion was not different between the groups (respectively 84 ± 2, 84 ± 3 and 84 ± 2%). The impaired serotonin-induced vasodilation could be attributed to a defect in nitric oxide production, since L-NMMA almost completely prevented serotonergic vasodilation. The defect in agonist-induced nitric oxide release or activity could not be explained by decreased substrate availability, as infusion of excess L-arginine (0.2 mg/kg/min) did not improve vasodilation. The nephrotic suhjects also had an increased lysophosphatidylcholine content in the low-density-lipoprotein fraction, which has been shown to interfere with Gi-protein-dependent signal transduction pathways, including serotonin-induced vasodilation. In conclusion, nephrotic-range proteinuria is accompanied by impaired endothelium-dependent vasomotion.
AB - Proteinuria is associated with increased cardiovascular morbidity and mortality. Release of nitric oxide by the endothelium has been advanced as an important defense mechanism against vessel-wall damage. In the present study we therefore tested the hypothesis that proteinuria is associated with a defect in nitric oxide-dependent vasodilation, by using venous occlusion plethysmography of the forearm in nine patients with nephrotic range proteinuria (>3.5 g/24 hr) and normal renal function (creatinine 83.1 ± 8.7 μmol/liter), eight patients with active glomerulonephritis but normal renal function (creatinine 81.2 ± 5.4 μmol/liter) and low range proteinuria (<1.0 g/24 hr), and ten healthy volunteers. We infused L-NMMA (2 mg/min) to inhibit basal nitric oxide production, serotonin, 0.1, 0.3 and 1.0 ng/kg/min) as an endothelium-dependent vasodilator, and nitroprusside (1, 10, 30 and 100 ng/kg/min) as an endothelium-independent vasodilator into the brachial artery. Administration of L-NMMA decreased basal forearm vascular resistance (FVR) By 30 ± 4% in the nephrotic subjects, 38 ± 4% in the non-nephrotic patients and by 37 ± 2% in the healthy controls (P = 0.15). Upon the highest dose of serotonin FVR decreased in nephrotic subjects by 40 ± 5%, which was less than in non-nephrotic patients (56 ± 3%; P < 0.05) or in healthy controls (55 ± 3%; P < 0.05). The maximal decrease in FVR upon nitroprusside infusion was not different between the groups (respectively 84 ± 2, 84 ± 3 and 84 ± 2%). The impaired serotonin-induced vasodilation could be attributed to a defect in nitric oxide production, since L-NMMA almost completely prevented serotonergic vasodilation. The defect in agonist-induced nitric oxide release or activity could not be explained by decreased substrate availability, as infusion of excess L-arginine (0.2 mg/kg/min) did not improve vasodilation. The nephrotic suhjects also had an increased lysophosphatidylcholine content in the low-density-lipoprotein fraction, which has been shown to interfere with Gi-protein-dependent signal transduction pathways, including serotonin-induced vasodilation. In conclusion, nephrotic-range proteinuria is accompanied by impaired endothelium-dependent vasomotion.
UR - http://www.scopus.com/inward/record.url?scp=0029119501&partnerID=8YFLogxK
U2 - 10.1038/ki.1995.325
DO - 10.1038/ki.1995.325
M3 - Article
C2 - 7564124
AN - SCOPUS:0029119501
SN - 0085-2538
VL - 48
SP - 544
EP - 550
JO - Kidney International
JF - Kidney International
IS - 2
ER -